For research use only. Not for therapeutic Use.
Bupranolol is an orally active, competitive and non-selective β-adrenoceptor antagonist without intrinsic sympathomimetic activity[1].
Bupranolol (1~3 μM) shifts isoprenaline-induced relaxation in the presence of 30 μM propranolol. Bupranolol acts as a competitive antagonist of isoprenaline-induced relaxation in the presence of 300 nM propranolol, with a pA2 value of 5.90. Bupranolol antagonizes β1- and β2-ARs with pA2 values of ≈9.0, and also antagonizes β3-AR with a pA2 value of 6.0[1].
| Catalog Number | R016039 |
| CAS Number | 14556-46-8 |
| Synonyms | 1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol |
| Molecular Formula | C14H22ClNO2 |
| Purity | ≥95% |
| InChI | InChI=1S/C14H22ClNO2/c1-10-5-6-12(15)13(7-10)18-9-11(17)8-16-14(2,3)4/h5-7,11,16-17H,8-9H2,1-4H3 |
| InChIKey | HQIRNZOQPUAHHV-UHFFFAOYSA-N |
| SMILES | CC1=CC(=C(C=C1)Cl)OCC(CNC(C)(C)C)O |
| Reference | [1]. Chino D, et al. Pharmacological identification of β-adrenoceptor subtypes mediating isoprenaline-induced relaxation of guinea pig colonic longitudinal smooth muscle. J Smooth Muscle Res. 2018;54(0):13-27. [2]. Babu RJ, et al. Effect of cyclodextrins on the complexation and transdermal delivery of bupranolol through rat skin. Int J Pharm. 2004;271(1-2):155-165. |
